Get started
Author

Nang Kham Su

Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
2020 · Oksana Zavidij, Nicholas J. Haradhvala, et al. · Nature Cancer · 369
Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma
2023 · Alexandre Detappe, Hung V.-T. Nguyen, et al. · Nature Nanotechnology · 104
PDF
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
2022 · Romanos Sklavenitis-Pistofidis, Michelle P. Aranha, et al. · Cancer Cell · 69
Progression signature underlies clonal evolution and dissemination of multiple myeloma
2020 · Yu Jia Shen, Yuji Mishima, et al. · Blood · 44
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology
2022 · Ankit K. Dutta, Jean-Baptiste Alberge, et al. · Cancer Discovery · 41
PDF
Genomic landscape of multiple myeloma and its precursor conditions
2025 · Jean-Baptiste Alberge, Ankit K. Dutta, et al. · Nature Genetics · 32
PDF
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia
2021 · Sabrin Tahri, Tarek H. Mouhieddine, et al. · Blood Advances · 27
Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma
2020 · Yaya Chu, Gaurav Nayyar, et al. · Journal for ImmunoTherapy of Cancer · 16
PDF
Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2019 · Mark Bustoros, MD, Omar Nadeem, et al. · Blood · 12
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
2025 · Elizabeth D. Lightbody, Romanos Sklavenitis-Pistofidis, et al. · Nature Cancer · 10
A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety
2019 · Omar Nadeem, Robert Redd, et al. · Blood · 10
Inhibition of MICA and MICB shedding enhances memory-like NK-cell–mediated cytotoxicity against multiple myeloma
2024 · Sabrin Tahri, Sara Piccinelli, et al. · Blood Advances · 8
Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+
2025 · Romanos Sklavenitis-Pistofidis, Elizabeth D. Lightbody, et al. · Blood · 6
Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
2022 · Elizabeth D. Lightbody, Danielle T. Firer, et al. · Blood · 4
Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma
2021 · Romanos Sklavenitis-Pistofidis, Ankit K. Dutta, et al. · Blood · 3
The PROMISE Study: A Nationwide Project for Predicting the Progression of Developing Myeloma in a High-Risk Screened Population
2019 · Annie Cowan, Allison Higgins, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
2024 · Jean-Baptiste Alberge, Ankit K. Dutta, et al. · Blood · 2
A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
2024 · Jean-Baptiste Alberge, Ankit K. Dutta, et al. · Blood · 2
PDF
High-Throughput Plasma Proteomics to Define the Precursor Multiple Myeloma Proteome and Identify Candidate High-Risk Disease Biomarkers of Progression
2023 · Elizabeth D. Lightbody, D. R. Mani, et al. · Blood · 2
Genome Sequencing to Discover Drivers of Clonal Expansion in Smoldering Multiple Myeloma
2023 · Jean-Baptiste Alberge, Ankit K. Dutta, et al. · Blood · 2
Author Correction: Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma
2023 · Alexandre Detappe, Hung V.-T. Nguyen, et al. · Nature Nanotechnology · 2
PDF
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors
2023 · Romanos Sklavenitis-Pistofidis, Elizabeth D. Lightbody, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease Pathology
2021 · Ankit K. Dutta, Elizabeth D. Lightbody, et al. · Blood · 2
Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
2024 · Junko Tsuji, Elizabeth D. Lightbody, et al. · Blood · 1
PDF
OA-40 SWIFT-Seq: Single-Cell RNA Sequencing of Circulating Tumor Cells as a Comprehensive Clinically Applicable Liquid Biopsy Test for Patients With Multiple Myeloma and Its Precursor Conditions
2024 · Elizabeth Lightbody, Romanos Sklavenitis-Pistofidis, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Works count: 63
Citation count: 779
H-index: 10
I10-index: 11
Year
Topic
Type